Clinical Trials » Macular Degeneration
AREDS II Supplement for AMD: National Eye Institute
|
NOT RECRUITING Description: The National Eye Institute is evaluating the anti-oxidants lutein and zeaxanthin, and the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) for their effect on reducing the risk of advanced age-related macular degeneration (AMD). Known as the Age-Related Eye Disease Study II (AREDS II), the five-year Phase III clinical trial has enrolled more than 4,000 participants at clinical sites across the U.S. The trial will be completed in December 2012. The first AREDS, completed in 2001, determined that a supplement containing beta carotene, vitamin C, vitamin E, and zinc reduced the risk of advanced AMD by 25 percent. Trial Status: Ongoing; not recruiting. Additional Information: AREDS II clinical trial listing on ClinicalTrials.gov |
